Furthermore, we analyzed the relationship between DCBLD2 expression level and chemotherapy sensitivity of tumor patients and found that patients with high DCBLD2 expression in Ovarian cancer and Breast cancer were less sensitive to drug therapy (Figure 6F). This evidence concerns the gene DCBLD2 and ovarian carcinoma.